Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Endocrine. 2017 Dec;58(3):467-473. doi: 10.1007/s12020-017-1461-8. Epub 2017 Oct 26.
Lugol's solution and other preparations containing iodide have for almost a century been used as an adjuvant treatment in patients with Graves' disease planned for thyroidectomy. Iodide has been shown to decrease thyroid hormone levels and reduce blood flow within the thyroid gland. An escape phenomenon has been feared as the iodide effect has been claimed to only be temporary. Lugol's solution has many additional effects and is used in other settings beside the thyroid. Still, there are questions of its mode of action, which doses should be deployed, if it should be used preoperative in all thyroidectomies or only in a few selected ones if at all, what is its use in other forms of thyrotoxicosis besides Graves' disease, and what is the mechanism acting on the vasculature and if these effects are confined only to arterial vessels supporting the thyroid or not. This review aims to collate current available data about Lugol's solution and other iodide preparations in the management of Graves' disease and give some suggestions where more research is needed.
卢戈氏液和其他含碘制剂近一个世纪以来一直被用作格雷夫斯病(Graves' disease)患者甲状腺切除术的辅助治疗。碘已被证明可降低甲状腺激素水平并减少甲状腺内的血流量。由于据称碘的作用只是暂时的,因此人们担心会出现逃逸现象。卢戈氏液除了在甲状腺外,还有许多其他用途和作用。但是,其作用机制、应该使用多大剂量、是否应该在所有甲状腺切除术术前使用,还是仅在少数选定的病例中使用,如果有的话、除了格雷夫斯病以外,在其他形式的甲状腺毒症中的用途是什么,以及作用于血管的机制,以及这些作用是否仅限于支持甲状腺的动脉血管,这些问题仍存在争议。本综述旨在整理关于卢戈氏液和其他碘制剂在格雷夫斯病治疗中的现有数据,并就需要进一步研究的领域提出一些建议。